Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide
- PMID: 8245792
- PMCID: PMC2191270
- DOI: 10.1084/jem.178.6.2207
Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide
Abstract
In this study we have examined the effects of interleukin 10 (IL-10) on polymorphonuclear leukocytes (PMN), and found that it is a potent inhibitor of tumor necrosis factor (TNF), IL-1 beta, and IL-8 secretion triggered by lipopolysaccharide (LPS). Cytokine production by phagocytosing PMN was also inhibited by IL-10, but to a lesser extent than the LPS-induced production. As shown by Northern blot analysis, IL-10 diminished the levels of TNF, IL-1 beta, and IL-8 mRNAs late after the onset of stimulation of PMN with LPS. In addition, we provide evidence that the kinetics of LPS-induced IL-8 production by PMN is composed of two distinct phases. Specifically, our experiments demonstrated that in the first phase, the production of IL-8 is a process directly induced by LPS that lasts for some hours. After this early wave, a second phase begins that is sustained and leads to an elevated production of IL-8 that appears to be due to the endogenous release of TNF and IL-1 beta. This second wave can in fact be blocked by anti-TNF and anti-IL-1 beta neutralizing antibodies, and by IL-10 as the consequence of its downregulatory effects on TNF and IL-1 beta release. Taken together, these findings identify novel biological actions of IL-10 as a suppressor of the inflammatory response.
Similar articles
-
Modulation of proinflammatory cytokine release from human polymorphonuclear leukocytes by gamma interferon.Cell Immunol. 1994 Sep;157(2):448-61. doi: 10.1006/cimm.1994.1241. Cell Immunol. 1994. PMID: 8069926
-
Secretion of IL-1 beta, TNF-alpha, IL-8 and IL-1ra by human polymorphonuclear leukocytes in response to lipopolysaccharides from periodontopathic bacteria.J Periodontal Res. 1997 Apr;32(3):279-86. doi: 10.1111/j.1600-0765.1997.tb00535.x. J Periodontal Res. 1997. PMID: 9138193
-
Interleukin-10 inhibits interleukin-8 production in human neutrophils.Blood. 1994 May 1;83(9):2678-83. Blood. 1994. PMID: 8167346
-
Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation.J Exp Med. 1994 May 1;179(5):1695-9. doi: 10.1084/jem.179.5.1695. J Exp Med. 1994. PMID: 8163946 Free PMC article.
-
[Modulation of the oxidative burst of human neutrophils by pro- and anti-inflammatory cytokines].Pathol Biol (Paris). 1996 Jan;44(1):36-41. Pathol Biol (Paris). 1996. PMID: 8734298 Review. French.
Cited by
-
Potential Targets to Mitigate Trauma- or Sepsis-Induced Immune Suppression.Front Immunol. 2021 Feb 25;12:622601. doi: 10.3389/fimmu.2021.622601. eCollection 2021. Front Immunol. 2021. PMID: 33717127 Free PMC article.
-
Modulation of Female Genital Tract-Derived Dendritic Cell Migration and Activation in Response to Inflammatory Cytokines and Toll-Like Receptor Agonists.PLoS One. 2016 May 12;11(5):e0155668. doi: 10.1371/journal.pone.0155668. eCollection 2016. PLoS One. 2016. PMID: 27171482 Free PMC article.
-
IL-10 mediated by herpes simplex virus vector reduces neuropathic pain induced by HIV gp120 combined with ddC in rats.Mol Pain. 2014 Jul 30;10:49. doi: 10.1186/1744-8069-10-49. Mol Pain. 2014. PMID: 25078297 Free PMC article.
-
Computational and Preclinical Evidence of Anti-ischemic Properties of L-Carnitine-Rich Supplement via Stimulation of Anti-inflammatory and Antioxidant Events in Testicular Torsed Rats.Oxid Med Cell Longev. 2021 Jul 5;2021:5543340. doi: 10.1155/2021/5543340. eCollection 2021. Oxid Med Cell Longev. 2021. PMID: 34326917 Free PMC article.
-
Proteomic analysis and functional validation reveal distinct therapeutic capabilities related to priming of mesenchymal stromal/stem cells with IFN-γ and hypoxia: potential implications for their clinical use.Front Cell Dev Biol. 2024 May 31;12:1385712. doi: 10.3389/fcell.2024.1385712. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 38882056 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials